News / Stock

USA: Pharma Industry, Axovant Accelerates On Genetic Therapies. Alphie Rewards The Stock.

May 22, 2020 - 14:08 GMT+0000

The company is headquartered in New York. Axovant Gene Therapies (AXGT_NAS), listed at the New York stock exchange in US Dollars, is a clinical-stage pharmaceutical company that develops gene therapies to treat neurological disorders. The company moves with urgency to develop and deliver innovative gene therapies that could transform the treatment of neurodegenerative diseases such as Parkinson’s. The company’s stock price has been relatively volatile since early April and can now be found at $3.54. The company’s market cap stands at 133.204M.    AlphieTMsuggests going long on the stock and predicts a possible upside of 5.35% in the next thirty…

Register to continue reading for free